PFIZER INC Quarterly Revenue from Contract with Customer, Excluding Assessed Tax in USD from Q2 2017 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Pfizer Inc annual/quarterly Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from Q2 2017 to Q4 2022.
  • Pfizer Inc Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending December 31, 2022 was $15.8B, a 2.68% decline year-over-year.
  • Pfizer Inc Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending December 31, 2022 was $91.8B, a 24.7% increase year-over-year.
  • Pfizer Inc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $50.9B, a 44.5% decline from 2022.
  • Pfizer Inc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $91.8B, a 24.7% increase from 2021.
  • Pfizer Inc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $73.6B, a 76.8% increase from 2020.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 $91.8B $15.8B -$434M -2.68% Oct 3, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 $92.2B $22.6B -$1.4B -5.81% Jul 4, 2022 Oct 2, 2022 10-Q 2022-11-09
Q2 2022 $93.6B $27.7B +$8.84B +46.8% Apr 4, 2022 Jul 3, 2022 10-Q 2022-08-10
Q1 2022 $84.8B $25.7B +$11.1B +76.8% Jan 1, 2022 Apr 3, 2022 10-Q 2022-05-11
Q4 2021 $73.6B $16.2B +$4.76B +41.6% Oct 4, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 $68.9B $24B +$13.8B +134% Jul 5, 2021 Oct 3, 2021 10-Q 2022-11-09
Q2 2021 $55.1B $18.9B +$9.04B +91.6% Apr 5, 2021 Jul 4, 2021 10-Q 2022-08-10
Q1 2021 $46.1B $14.5B +$4.43B +44% Jan 1, 2021 Apr 4, 2021 10-Q 2022-05-11
Q4 2020 $41.7B $11.4B +$9.58B +520% Sep 28, 2020 Dec 31, 2020 10-K 2022-02-24
Q3 2020 $32.1B $10.3B -$2.4B -19% Jun 29, 2020 Sep 27, 2020 10-Q 2021-11-12
Q2 2020 $34.5B $9.86B -$3.4B -25.6% Mar 30, 2020 Jun 28, 2020 10-Q 2021-08-12
Q1 2020 $37.9B $10.1B -$3.04B -23.1% Jan 1, 2020 Mar 29, 2020 10-Q 2021-05-13
Q4 2019 $40.9B $1.84B +$688M +59.6% Sep 30, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 $40.2B $12.7B -$618M -4.65% Jul 1, 2019 Sep 29, 2019 10-Q 2020-11-05
Q2 2019 $40.8B $13.3B -$202M -1.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $41B $13.1B +$212M +1.64% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $40.8B $1.16B Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $13.3B +$130M +0.99% Jul 2, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $13.5B +$570M +4.42% Apr 2, 2018 Jul 1, 2018 10-Q 2019-08-08
Q1 2018 $12.9B Jan 1, 2018 Apr 1, 2018 10-Q 2019-05-09
Q3 2017 $13.2B Jul 3, 2017 Oct 1, 2017 10-Q 2018-11-08
Q2 2017 $12.9B Apr 3, 2017 Jul 2, 2017 10-Q 2018-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.